MODEYSO (Dordaviprone Hydrochloride) Patent Expiration, LOE Window & CMS Spending

MODEYSO (Dordaviprone Hydrochloride) by Chimerix: FDA Orange Book core substance LOE 2036-03-01 (last listed 2037-01-30), 0 AB generics, $0 2024 CMS Part D & Medicaid spend, and $32,000 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorChimerix
FDA Application & PathwayN219876 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2036-03-01
Last Listed Patent or Exclusivity Date2037-01-30
Orange Book Patents (*PED Extensions)7 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$0
2024 Medicare Part D Spend$0
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($32,000 intro WAC)